Senti Biosciences, Inc. (SNTI)

NASDAQ: SNTI · IEX Real-Time Price · USD
2.25
-0.05 (-2.17%)
Dec 2, 2022 4:00 PM EST - Market closed
-2.17%
Market Cap 100.87M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 43.42M
EPS (ttm) -3.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,938
Open 2.37
Previous Close 2.3
Day's Range 2.22 - 2.38
52-Week Range 1.2 - 10.35
Beta n/a
Analysts Buy
Price Target 9.01 (+300.4%)
Earnings Date Nov 21, 2022

About SNTI

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells... [Read more]

Industry Biotechnology
Founded 2016
Employees 89
Stock Exchange NASDAQ
Ticker Symbol SNTI
Full Company Profile

Financial Performance

In 2021, SNTI's revenue was $2.76 million, an increase of 387.81% compared to the previous year's $566,000. Losses were -$55.32 million, 178.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for SNTI stock is "Buy." The 12-month stock price forecast is 9.01, which is an increase of 300.44% from the latest price.

Price Target
$9.01
(300.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML –

1 week ago - GlobeNewsWire

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33 and/or FLT3 expressing hematologic malignancies including MDS -

3 weeks ago - GlobeNewsWire

Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expres...

1 month ago - GlobeNewsWire

Senti Bio Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its ...

1 month ago - GlobeNewsWire

7 Best Penny Stocks Under $3 to Buy Now

While the below market ideas may very well represent the best penny stocks under $3 to buy now, you must realize the dirty little secret. Usually, when publicly traded securities fall this low, it's not...

Other symbols: CTVWKHS
1 month ago - InvestorPlace

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

Abstracts highlight Senti Bio's continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors Abstracts ...

1 month ago - GlobeNewsWire

Senti Bio to Participate in Chardan's 6th Annual Genetic Medicines Conference

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its...

2 months ago - GlobeNewsWire

Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its...

2 months ago - GlobeNewsWire

Chardan Announces Launch of ChEF (Chardan Equity Facility)

NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution used to support the un...

3 months ago - PRNewsWire

Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its ...

3 months ago - GlobeNewsWire

Senti Bio Reports Second Quarter Financial Results and Business Updates

- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 -

3 months ago - GlobeNewsWire

SNTI Stock Alert: What to Know About Red-Hot Senti Biosciences Today

On most days, Senti Biosciences (NASDAQ: SNTI ) flies under the radar on Wall Street. Today, however, is different as SNTI stock is flying high.

4 months ago - InvestorPlace

Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with ...

- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combinatio...

6 months ago - GlobeNewsWire

Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-...

10 months ago - GlobeNewsWire

Synthetic Biology Platform Senti Bio Rides On Omid Farokhzad's SPAC For NASDAQ Debut

Senti Biosciences Inc, the synthetic biology play helmed by MIT whiz Tim Lu, will be merging with Farokhzad's Dynamics Special Purpose Corp (NASDAQ: DYNS) in a deal set to deliver $296 million in gross ...

Other symbols: AMGN
11 months ago - Benzinga

Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Compan...

- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock...

11 months ago - GlobeNewsWire

Cathie Wood Makes Adjustments to Portfolio in August

Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.

Other symbols: FATEMASSQSIVUZI
1 year ago - GuruFocus

Dynamics Special Purpose Corp. Announces Pricing of $200 Million Initial Public Offering

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dynamics Special Purpose Corp. Announces Pricing of $200 Million Initial Public Offering

1 year ago - Business Wire